| Literature DB >> 35340912 |
Bingtao Gao1,2,3, Anthony A Rojas Chavez4,1, Walla I Malkawi5, Daniel W Keefe1,2,3, Rasheid Smith5, Hillel Haim4, Aliasger K Salem5,6, Fatima Toor1,7,2,6,3.
Abstract
The COVID-19 pandemic has caused tremendous damage to the world. In order to quickly and accurately diagnose the virus and contain the spread, there is a need for rapid, sensitive, accurate, and cost-effective SARS-CoV-2 biosensors. In this paper, we report on a novel biosensor based on angiotensin converting enzyme 2 (ACE-2)-conjugated vertically-oriented silicon nanowire (vSiNW) arrays that can detect the SARS-CoV-2 spike protein with high sensitivity and selectivity relative to negative controls. First, we demonstrate the efficacy of using ACE-2 receptor to detect the SARS-CoV-2 spike protein via a capture assay test, which confirms high specificity of ACE-2 against the mock protein, and high affinity between the spike and ACE-2. We then report on results for ACE-2-conjugated vSiNW arrays where the biosensor device architecture is based on a p-n junction transducer. We confirm via analytical modeling that the transduction mechanism of the biosensor involves induced surface charge depletion of the vSiNWs due to negative electrostatic surface potential induced by the spike protein after binding with ACE-2. This vSiNW surface charge modulation is measured via current-voltage characteristics of the functionalized biosensor. Calibrated concentration dependent electrical response of the vSiNW sensor confirms the limit-of-detection for virus spike concentration of 100 ng/ml (or 575 pM). The vSiNW sensor also exhibits highly specific response to the spike protein with respect to negative controls, offering a promising point-of-care detection method for SARS-CoV-2.Entities:
Keywords: COVID-19; Label-free detection; Metal-assisted chemical etching (MACE); Point-of-care device; SARS-CoV-2; Silicon nanowire biosensor
Year: 2022 PMID: 35340912 PMCID: PMC8937609 DOI: 10.1016/j.sbsr.2022.100487
Source DB: PubMed Journal: Sens Biosensing Res ISSN: 2214-1804
Fig. 1vSiNW biosensor and the encapsulation for SARS-CoV-2 detection. (a) Schematics of the detection mechanism of the vSiNW biosensor. Spike proteins exist on the surface of SARS-CoV-2, and the spike can specifically bind to the ACE-2 protein that is immobilized on the surface of vSiNWs. Negative electrostatic surface potential is induced by the spike protein after binding, which enhances the surface recombination effect if the vSiNWs are n+-doped. (b) Photo of a fabricated vSiNW biosensor. (c) Titled top and cross-sectional view schematic diagrams of the vSiNW biosensor. (d) Structural schematic of the ABS encapsulation of the vSiNW sensor, the assembly starts from the bottom. (e) I(V) testing system of the vSiNW biosensor with the sensor encapsulation, an external source meter, the analyte on the sensing area, and an ABS cover on top.
Fig. 2Design and validation of the ACE-2-Fc and Spike-Fc soluble probes. (a) Composition of the ACE-2-Fc chimeric protein. The extracellular domain of human ACE-2 was fused to the Fc region of human IgG1. A thrombin cleavage site was introduced to allow removal of the Fc region. (b) Analysis of the purity and size of the ACE-2-Fc and Spike-Fc probes by polyacrylamide gel electrophoreses, followed by silver staining. (c) Detection of the ACE-2-Fc probe by cell-based ELISA. HOS cells were transfected to express on their surface the SARS-CoV-2 spike protein. As controls, some samples were transfected with an empty (mock) vector. Binding of ACE-2-Fc to the cells was detected using an HRP-conjugated goat anti-human IgG preparation. Significance of the differences between binding to cells that express spike and mock-transfected cells was calculated using an unpaired t-test: *, p < 0.05; **; p ≤ 0.005; ***, p ≤ 0.0005. (d) Composition of the soluble Spike-Fc probe. To generate a probe that contains both S1 and S2 subunits, the furin cleavage site was disrupted by substitution of the Arg-Arg-Ala-Arg motif to Ser-Ser-Ala-Ser. (e) Measurements of Spike-Fc binding to HOS cells transfected by a plasmid that expresses the ACE-2 protein or a negative control (mock) plasmid.
Fig. 3Study of the three-diode model for the vSiNW biosensor. (a) Equivalent circuit diagram of the proposed three-diode model for the vSiNW biosensor. (b) Example schematic diagram of the possible location of each component of the circuit in (a). Variations of simulated ID-VD curve for different values of I0H and RH = 100 Ω (c) and 1000 Ω (d). Other parameters: I01 = 10−11 A, I02 = 1 × 10−7 A, n1 = 1, n2 = 2, nH = 2.5, Rs = 0 Ω, Rsh → ∞.
Fig. 4Calibration of I(V) curves. Measured I(V) curves of an AS (a) and a BB sensor (b). Calibrated I(V) (ID-VD) curves of the AS (c) and the BB sensor (d).
Fig. 5Specificity and concentration response results of the vSiNW biosensor for spike protein detection. (a) Statistics of ΔID% at VD = 100 mV for the positive test AS and three negative control tests AB, BS, and BB. (b) ΔID% at VD = 100 mV of the ACE-2-functionalized vSiNW biosensors at different concentrations of spike testing solutions, where the black circle represents the ΔID% for 0 ng/ml. (*: p < 0.05, **: p < 0.01, unpaired t-test between AS and each control group).